Sanofi

EIT Health launches the WorkInHealth Foundation

It will seek sponsorship from its existing partners, including Atos and Sanofi, alongside garnering support from bigger tech corporations like Apple, Microsoft and Amazon.

Sanofi’s asthma treatment approved by European Commission

Naimish Patel is head of global development, Immunology and Inflammation at Sanofi, and spoke about bringing the well-established safety and efficacy of Dupixent to an even younger group of patients

Sanofi launches Diversity, Equity & Inclusion Board

Sanofi has launched a Diversity, Equity &Inclusion (DE&I) Board. The Board will feature outside advisors, a first in the pharmaceutical industry. ... Paul Hudson, CEO of Sanofi, said: “We’re committed to driving diversity, equity and inclusion in

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

development, regulatory and commercial milestones. Sanofi has also expressed an interest in buying up to $100m of IGM non-voting common stock. ... This partnership builds on an existing research collaboration with Sanofi and is a key step towards.

Sanofi and Regeneron share positive trial results for patients with uncontrolled prurigo nodularis

Positive results from the phase 3 PRIME2 trial – part of the LIBERTY-PN PRIME clinical programme – assessing the safety and effectiveness of Sanofi and Regeron’s Dupixent (dupilumab) were shared in ... Previously, Sanofi and Regeneron announced

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]